<DOC>
	<DOCNO>NCT00864305</DOCNO>
	<brief_summary>To compare relative bioavailability gabapentin 400 mg capsule ( Purepac ) NEURONTIN® 400 mg capsule ( Parke-Davis ) healthy adult male subject non-fasting condition , compare difference plasma level dose test formulation without food</brief_summary>
	<brief_title>A Relative Bioavailability Study Gabapentin 400 mg Capsules Under Non-fasting Conditions</brief_title>
	<detailed_description>Study Type : Interventional Study Design : Single dose , randomize , three-period , three-treatment , six-sequence crossover study non-fasting condition ( test reference ) fasting ( test ) condition Official Title : A relative Bioavailability Food Challenge Study Gabapentin 400 mg Capsules Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Rate Extend Absorption</detailed_description>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>All subject select study male 18 45 ( inclusive ) year age . Weight range subject shall 135246 pound , individual weight variation 10 % ± normal height body frame ( Metropolitan Life , 1983 , Height , Weight , Body Chart ) . Each subject shall give general physical examination within 21 day initiation study . Such examination include , limited , blood pressure , general observation , history . At end study , subject exit evaluation consist interim history , global evaluation , clinical laboratory measurement . Adequate blood urine sample obtain within 21 day begin first period end trial clinical laboratory measurement . Clinical laboratory measurement include follow : Hematology : hemoglobin , hematocrit , red blood cell count , platelet , white blood cell count ( differential ) . Clinical Chemistry : creatinine , BUN , glucose , SGOT , SGPT , bilirubin , alkaline phosphate Urine Analysis : pH , specific gravity , protein , glucose , ketone , bilirubin , occult blood , cell . HTLV III Screen : ( prestudy ) HepatitisB Surface Ag Screen : ( prestudy ) Drugs Abuse Screen : ( prestudy ) Subjects select normal . Subjects history chronic alcohol consumption , drug addition , serious gastrointestinal , renal , hepatic cardiovascular disease , tuberculosis , epilepsy , asthma , diabetes , psychosis glaucoma eligible study . Subjects whose clinical laboratory test value great 20 % outside normal range may restrict . If clinical value outside range testing , subject eligible participate study unless clinical investigator deem result significant . Subjects history allergic response class drug test exclude study . Subjects use tobacco form eligible participate study . Three month abstinence require . All subject urine sample assay presence drug abuse part clinical laboratory screening procedure . Subjects find urine concentration test drug allow participate . Subjects donate blood and/or plasma least thirty ( 30 ) day prior start study . Subjects take investigational drug within thirty ( 30 ) day prior start study allow participate . Subjects expose know hepatic enzyme induct inhibit agent within thirty ( 30 ) day prior dose allow participate .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Gabapentin</keyword>
	<keyword>Healthy subject</keyword>
</DOC>